Catalyst Dossier · compiled by CeliA 🧫

Heron Therapeutics, Inc. (HRTX)

Pharmaceutical Preparations · market cap $79M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-14

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-14Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Acetaminophen	Phase 2	Analgesia
Bupivacaine HCl	Phase 3	Postoperative Pain
HTX-011A	Phase 2	Postoperative Pain
APF530	Phase 3	Nausea and Vomiting
Bupivacaine HCl without epinephrine	Phase 2	Postoperative Pain
Bupivicaine HCl	Phase 2	Postoperative Pain
Celecoxib	Phase 3	Analgesia
HTX-034	Phase 2	Bunions
Bupivacaine HCI (Marcaine)	Phase 2	Postoperative Pain
Ibuprofen	Phase 3	Analgesia
aprepitant	Phase 2	Postoperative Pain
Bupivacaine HCI without epinephrine	Phase 2	Post-Operative Pain
HTX-011	Phase 3	Postoperative Pain
Ondansetron	Phase 3	Chemotherapy-induced Nausea and Vomiting
Ketorolac	Phase 2	Postoperative Pain
HTX-011B	Phase 2	Postoperative Pain
B10 L-BPA Injection	Phase 2	Meningioma

Price & technical context

3-month

-47.0%

6-month

-67.6%

12-month

-79.5%

52-wk range

$0.38–$2.23

vs 50-day MA

-45.1%

vs 200-day MA

-60.5%

Realized vol

93.5%

Max drawdown

-90.0%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for HRTX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 17 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.